vs
Side-by-side financial comparison of DXC Technology Co (DXC) and Zoetis (ZTS). Click either name above to swap in a different company.
DXC Technology Co is the larger business by last-quarter revenue ($3.2B vs $2.3B, roughly 1.4× Zoetis). Zoetis runs the higher net margin — 26.6% vs 3.4%, a 23.2% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (2.9% vs -1.0%). Over the past eight quarters, Zoetis's revenue compounded faster (-2.1% CAGR vs -2.9%).
DXC Technology Company is an American multinational information technology (IT) services and consulting company headquartered in Ashburn, Virginia.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
DXC vs ZTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.2B | $2.3B |
| Net Profit | $107.0M | $601.0M |
| Gross Margin | — | 71.7% |
| Operating Margin | 8.2% | — |
| Net Margin | 3.4% | 26.6% |
| Revenue YoY | -1.0% | 2.9% |
| Net Profit YoY | 87.7% | -0.2% |
| EPS (diluted) | $0.61 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.3B | ||
| Q4 25 | $3.2B | $2.4B | ||
| Q3 25 | $3.2B | $2.4B | ||
| Q2 25 | $3.2B | $2.5B | ||
| Q1 25 | $3.2B | $2.2B | ||
| Q4 24 | $3.2B | $2.3B | ||
| Q3 24 | $3.2B | $2.4B | ||
| Q2 24 | $3.2B | $2.4B |
| Q1 26 | — | $601.0M | ||
| Q4 25 | $107.0M | $603.0M | ||
| Q3 25 | $36.0M | $721.0M | ||
| Q2 25 | $16.0M | $718.0M | ||
| Q1 25 | $264.0M | $631.0M | ||
| Q4 24 | $57.0M | $581.0M | ||
| Q3 24 | $42.0M | $682.0M | ||
| Q2 24 | $26.0M | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | 8.2% | 31.9% | ||
| Q3 25 | 8.0% | 37.0% | ||
| Q2 25 | 6.8% | 36.7% | ||
| Q1 25 | 7.3% | 36.5% | ||
| Q4 24 | 8.9% | 31.6% | ||
| Q3 24 | 8.6% | 36.6% | ||
| Q2 24 | 6.9% | 33.0% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | 3.4% | 25.3% | ||
| Q3 25 | 1.1% | 30.0% | ||
| Q2 25 | 0.5% | 29.2% | ||
| Q1 25 | 8.3% | 28.4% | ||
| Q4 24 | 1.8% | 25.1% | ||
| Q3 24 | 1.3% | 28.6% | ||
| Q2 24 | 0.8% | 26.4% |
| Q1 26 | — | $1.42 | ||
| Q4 25 | $0.61 | $1.37 | ||
| Q3 25 | $0.20 | $1.63 | ||
| Q2 25 | $0.09 | $1.61 | ||
| Q1 25 | $1.42 | $1.41 | ||
| Q4 24 | $0.31 | $1.29 | ||
| Q3 24 | $0.23 | $1.50 | ||
| Q2 24 | $0.14 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | — |
| Total DebtLower is stronger | $3.1B | — |
| Stockholders' EquityBook value | $3.1B | — |
| Total Assets | $13.2B | — |
| Debt / EquityLower = less leverage | 0.98× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.9B | $2.1B | ||
| Q2 25 | $1.8B | $1.4B | ||
| Q1 25 | $1.8B | $1.7B | ||
| Q4 24 | $1.7B | $2.0B | ||
| Q3 24 | $1.2B | $1.7B | ||
| Q2 24 | $1.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $3.1B | — | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $3.6B | — | ||
| Q3 24 | $3.8B | — | ||
| Q2 24 | $3.8B | — |
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $3.3B | ||
| Q3 25 | $3.1B | $5.4B | ||
| Q2 25 | $3.2B | $5.0B | ||
| Q1 25 | $3.2B | $4.7B | ||
| Q4 24 | $3.0B | $4.8B | ||
| Q3 24 | $3.0B | $5.2B | ||
| Q2 24 | $2.9B | $5.0B |
| Q1 26 | — | — | ||
| Q4 25 | $13.2B | $15.5B | ||
| Q3 25 | $13.6B | $15.2B | ||
| Q2 25 | $13.4B | $14.5B | ||
| Q1 25 | $13.2B | $14.1B | ||
| Q4 24 | $13.0B | $14.2B | ||
| Q3 24 | $13.5B | $14.4B | ||
| Q2 24 | $13.4B | $14.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.98× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.98× | — | ||
| Q1 25 | 0.93× | — | ||
| Q4 24 | 1.22× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.32× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $414.0M | — |
| Free Cash FlowOCF − Capex | $359.0M | — |
| FCF MarginFCF / Revenue | 11.2% | — |
| Capex IntensityCapex / Revenue | 1.7% | — |
| Cash ConversionOCF / Net Profit | 3.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $414.0M | $893.0M | ||
| Q3 25 | $409.0M | $938.0M | ||
| Q2 25 | $186.0M | $486.0M | ||
| Q1 25 | $315.0M | $587.0M | ||
| Q4 24 | $650.0M | $905.0M | ||
| Q3 24 | $195.0M | $951.0M | ||
| Q2 24 | $238.0M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $359.0M | $732.0M | ||
| Q3 25 | $365.0M | $805.0M | ||
| Q2 25 | $143.0M | $308.0M | ||
| Q1 25 | $238.0M | $438.0M | ||
| Q4 24 | $568.0M | $689.0M | ||
| Q3 24 | $154.0M | $784.0M | ||
| Q2 24 | $190.0M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 11.2% | 30.7% | ||
| Q3 25 | 11.5% | 33.5% | ||
| Q2 25 | 4.5% | 12.5% | ||
| Q1 25 | 7.5% | 19.7% | ||
| Q4 24 | 17.6% | 29.7% | ||
| Q3 24 | 4.8% | 32.8% | ||
| Q2 24 | 5.9% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.7% | 6.7% | ||
| Q3 25 | 1.4% | 5.5% | ||
| Q2 25 | 1.4% | 7.2% | ||
| Q1 25 | 2.4% | 6.7% | ||
| Q4 24 | 2.5% | 9.3% | ||
| Q3 24 | 1.3% | 7.0% | ||
| Q2 24 | 1.5% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 3.87× | 1.48× | ||
| Q3 25 | 11.36× | 1.30× | ||
| Q2 25 | 11.63× | 0.68× | ||
| Q1 25 | 1.19× | 0.93× | ||
| Q4 24 | 11.40× | 1.56× | ||
| Q3 24 | 4.64× | 1.39× | ||
| Q2 24 | 9.15× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DXC
| GIS Segment | $1.6B | 50% |
| CES Segment | $1.3B | 40% |
| Insurance Segment | $321.0M | 10% |
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
